| Digital Ally (NASDAQ: DGLY) Receives Multiple Upgrade Orders |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced video recording products for law enforcement, emergency management, fleet safety and security, announced the receipt of notable orders from the Santa Fe, New Mexico Police Department for its DVM-800 in-car video event recorders and patented VuLink® auto-activation systems.
Why It Matters: The Santa Fe Police Department has been a customer of Digital Ally for almost a decade, deploying multiple legacy systems as well as continuing to upgrade its technology. These orders include an additional 26 of the Company’s flagship DVM-800 in-car video event recorders and 26 patented VuLink® auto-activation systems. The DVM-800 system is a solid-state unit used to capture critical events that take place during an officer’s shift. Paired with the Company’s patented VuLink® system, the DVM-800 system will automatically start a recording when activated by a variety of triggers.
The Backstory: Headquartered in Lenexa, KS, Digital Ally specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, fleet safety and security. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, beginning in September 2017, for RedChip investor awareness services.
|
|
| |
|
| Can-Fite BioPharma (NYSE American: CANF) Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study |
| |
|
Can-Fite BioPharma (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, completed enrollment of approximately 50% of the 525 patients planned for its Phase III ACRobat™ trial to evaluate its drug candidate Piclidenoson as a first-line treatment for rheumatoid arthritis (RA).
Why It Matters: The Phase III ACRobat™ RA study is designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to methotrexate in patients with RA. An estimated 90% of RA patients receive methotrexate at some point in their disease. However, studies show that up to 50% of patients stop taking methotrexate due to reasons including drug intolerance, minor and major side effects, and lack of efficacy, creating a significant need for a new, safe and effective treatment option in the RA treatment market.
Key Quote: “With just over half the patients enrolled in this pivotal Phase III study, we have achieved an important milestone and we believe Piclidenoson is a potentially efficacious drug that can be safely used long-term on a daily basis by patients for chronic conditions. The interim analysis by the IDMC, we believe will facilitate the most efficient use of corporate resources, especially with respect to continuing the current study and planning our second Phase 3 trial.” – Dr. Pnina Fishman, CEO
The Backstory: Can-Fite is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the FDA. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.
Disclosure
Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a cash fee of $5,000 monthly, beginning in August 2019, and 16,500 shares of CANF Rule 144 stock for 6 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) Files December 2019 Quarterly Report |
| |
|
Piedmont Lithium (NASDAQ: PLL) filed its quarterly report for the period ended December 31, 2019. Highlights include:
- Completed federal permitting required to develop the proposed mine and concentrator at the Company’s Kings Mountain, North Carolina project
- Appointed Hatch to deliver a pre-feasibility study ("PFS") for the Company’s proposed lithium hydroxide chemical plant in Kings Mountain
- In response to strong interest from prospective lithium hydroxide customers, the Company is accelerating the development of its lithium chemical plant by compressing its project timeline into a single-stage, effectively accelerating chemical plant development by one year while deferring the mine and concentrator construction start date by one year, resulting in integrated operations from day one
- Completed the Company’s Phase 4 drill program, which comprised 113 holes for a total of 18,393 meters. The Phase 4 drill program was successful in expanding the Project’s mine life from 13 to 25 years
- Soil and rock chip sampling led to the discovery of five new spodumene-bearing pegmatites in areas that have not previously been explored
Upcoming Milestones:
- Complete the PFS for the chemical plant in Q2 2020
- Finalize the bench scale lithium hydroxide testwork program and produce initial product samples
- Continue offtake discussions for lithium hydroxide with participants in the global battery supply chain
- Continue to evaluate strategic partnering options
The Backstory: PLL holds a 100% interest in the Piedmont Lithium Project located within the world-class Carolina TinSpodumene Belt and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world’s lithium between the 1950s and the 1980s. The TSB has been described as one of the largest lithium provinces in the world and is located approximately 25 miles west of Charlotte, North Carolina. It is a premier location for development of an integrated lithium business based on its favorable geology, proven metallurgy and easy access to infrastructure, power, R&D centers for lithium and battery storage, major high-tech population centers and downstream lithium processing facilities.
Disclosure
Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a quarterly cash fee of $20,000, beginning in April 2019, for 12 months of RedChip investor awareness services.
|
|
| |
|
| 1847 Holdings (OTC: EFSH) Signs LOI to Acquire Multi-State Retail Hydroponic Supply Operation |
| |
|
1847 Holdings (OTC: EFSH) , a unique publicly traded holding company platform that combines the attractive attributes of private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, signed a non-binding Letter of Intent (LOI) to acquire a multi-state retail hydroponic supply operation and has formed a new wholly-owned subsidiary, 1847 Hydroponic, Inc., in preparation of completing the transaction.
Why It Matters: The hydroponics systems market is projected to grow at CAGR of 12.1% over the next six years, from $8.1 billion in 2019 to $16 billion in 2025, according to analysts at MarketsandMarkets Research.
Key Quote: “This acquisition will give 1847 the ability to participate in the high-growth hemp and cannabis market without touching the plant or incurring the burdensome regulatory requirements and challenges of traditional cannabis operations focused on cultivation and end-product sales. With our team's extensive experience in high-growth retail operations, we're confident we can rapidly scale this business moving forward.” – Ellery W. Roberts, Founder & CEO
The Backstory: 1847 employs a unique public company holding platform that combines the attractive attributes of private, lower-middle market businesses with the liquidity and transparency of a publicly traded company. Its only public-company comp, Compass Diversified Holding (NYSE: CODI), has a current market cap in excess of $1 billion and is up 344% since its 2006 IPO, compared to 193% for the S&P 500 and 163% for the Russell 2000 over the same period. 1847’s initial two acquisitions generate a combined $64.18 million in annual revenue with opportunities for growth and margin improvement through additional resources and implementation of return- driven metrics and accountability. Leveraging an expansive network of deal flow contacts in a niche of the private company arena often overlooked by investment banks and larger private equity funds, 1847 is ideally positioned to scale and manage its portfolio.
Disclosure
1847 Holdings (EFSH) is a client of RedChip Companies, Inc. EFSH agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in November 2019, and 100,000 restricted common shares of EFSH stock for 12 months of RedChip investor awareness services.
|
|
| |
|
| Immuron’s (NASDAQ: IMRN) Technology Platform of Treatments in the Age of the Coronavirus Outbreak |
| |
|
Immuron (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, announced that its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan® has potential to address the ongoing risks of travel to sites endemic for travelers’ diarrhea, as the focus turns to the ensuing health crises brought on by the Wuhan coronavirus outbreak and its rapid spread.
Why It Matters: The current crisis highlights the risks associated with modern day international travel. Parasites, viruses, food and water contaminated with pathogenic bacteria such as enterotoxigenic Escherichia coli (E.coli), enteroaggregative E.coli, Campylobacter, Salmonella, and Shigella are a constant threat to all international travellers. Over 68 million Americans traveled abroad in 2014, and approximately 65% of these trips were to high risk destinations. Among travelers from developed countries who visit developing countries, 30 to 70% may experience traveler’s diarrhea. The annual number of international tourist arrivals worldwide has reached more than 1 billion.
Key Quote: “We are seeing the dramatic effects that global travel is having on the potential spread of the newly identified Wuhan coronavirus. While the major danger is due to the respiratory repercussions with this highly infectious agent, there are now reports coming forth regarding patients presenting with gastrointestinal symptoms as well.” - Dr. Gary S. Jacob, CEO
The Backstory: Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licenced natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA). Immuron’s lead clinical candidate, IMM-124E, contains the same active pharmaceutical ingredient as Travelan®.
Disclosure
Immuron Ltd. (IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a $7,500 monthly cash fee, beginning in June 2017, for investor awareness services.
|
|
| |
|
| SPI Energy (NASDAQ: SPI) Provides Update on its CBD Operations |
| |
|
SPI Energy (NASDAQ: SPI), a global provider of green energy solutions with strategic investments in green-energy-enabled products and services, recently completed the installation of its cannabidiol (CBD) extraction equipment at a facility in Fresno, California.
Why It Matters: The newly installed CBD extraction equipment is designed to enable the production of CBD crude oil, distillate and isolate. Currently, the Company is conducting pre-production test runs of its CBD crude oil extraction process; completing quality control review, and self-testing the CBD crude oil that is being produced.
Key Quote: “We have made significant progress building the foundation of our CBD operations in California in recent months. The Company has executed toll manufacturing agreements with three local hemp farms, and we expect to expand our CBD extraction services and scale our production capacity to match growing demand.” - Xiaofeng Peng, Chairman and CEO
The Backstory: SPI is an established provider of photovoltaic solutions with global operations in key markets in Australia, Europe, Japan and the United States. The Company is leveraging its solar platform and expertise to make strategic investment in green industries with significant growth and earnings potential and/or green-energy-enabled products.
Disclosure
SPI Energy (SPI) is a client of RedChip Companies, Inc. SPI agreed to pay RedChip Companies, Inc. 25,000 shares of Rule 144 stock and a monthly cash fee of $6,500, beginning in August 2019, for 12 months of RedChip investor awareness services and consulting services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Subsidiary Direct Solar Reports Strong Start to 2020 |
| |
|
SinglePoint (OTCQB: SING) subsidiary, Direct Solar America, has closed its initial set of sales through the partnership agreement with My Home Group Real Estate, the fastest growing residential real estate brokerage in Arizona, the second fastest in the nation.
Why It Matters: In Q1 2019, the U.S. solar market surpassed 2 million installations - just three years after the market surpassed the 1 million installation milestone. The industry is expected to hit 3 million installations in 2021 and 4 million installations in 2023. This is a result of increased demand by consumers due to reduced installation costs as well as increasing environmental awareness which is driving the adoption of cost-efficient alternative and renewable forms of energy over conventional energy sources.
Key Quote: “We see this partnership being a major force for new business and increased solar systems installed throughout the U.S. through Direct Solar America. It is exciting to see the results start to come through after ironing out the process and being able to train My Home Group agents. As we continue to collaborate, we believe this could more than double the current output of Direct Solar Americas current residential operations.” – Greg Lambrecht, CEO
The Backstory: SinglePoint invests in and acquires brands and companies that will benefit from an injection of growth capital and the sales and marketing expertise of SinglePoint. The Company’s portfolio is focused on renewable energy specifically solar and has holdings in hemp and payments. SinglePoint is working to grow the company to a multinational entity.
Disclosure
SinglePoint, Inc. (SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in June 2019, for RedChip investor awareness services and consulting services.
|
|
| |
|
| |
| Quote of the Week |
| |
"Be wary of bad management teams, don’t bet on dreams. Do your homework and be careful."
- Dave Maley, Manager Ariel Discovery Fund |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2020 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
